Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - The company has experienced significant growth following the updated label for its cardiovascular outcomes trial, expanding its addressable market from approximately 10 million patients to 70 million patients [2] - The company has demonstrated double-digit growth quarter-over-quarter since the label update, indicating strong market uptake and acceptance [2][3] - The product has transitioned from a niche offering to one of the most broadly labeled cardiovascular drugs, reflecting a major shift in its market positioning [2] Company Progress - The updated label received in April 2024 has been a watershed moment for the company, allowing for broader sales strategies and market penetration [2] - The company has made substantial progress in engaging with major payers in the reimbursement landscape, enhancing its market presence [3]